Firefly Neuroscience, Inc. (AIFF)
| Market Cap | 14.43M -47.1% |
| Revenue (ttm) | 1.80M +320.3% |
| Net Income | -9.44M |
| EPS | -0.60 |
| Shares Out | 15.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,165 |
| Open | 1.0300 |
| Previous Close | 1.0200 |
| Day's Range | 0.9196 - 1.0300 |
| 52-Week Range | 0.6175 - 3.1500 |
| Beta | -4.04 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About AIFF
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for vari... [Read more]
Financial Performance
In 2025, Firefly Neuroscience's revenue was $1.14 million, an increase of 957.41% compared to the previous year's $108,000. Losses were -$24.53 million, 134.5% more than in 2024.
Financial StatementsNews
Firefly, NeuroSigma partner to expand awareness, access to Monarch eTNS
Firefly Neuroscience (AIFF) and NeuroSigma announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS System through Firefly’s growing nationwide networ...
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
– Partnership will introduce NeuroSigma's second-generation Monarch eTNS ® System to Firefly's nationwide network of Evoke™ clinicians –
Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine
– This integration of Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial's August 2026 acquisition of the management services organization supporting Mindful Health Solutions,...
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, tod...
Firefly Neuroscience partners with Next Health on cognitive health platform
Firefly Neuroscience (AIFF) and Next Health, a global leader in health optimization and longevity, announced a strategic partnership to launch a precision cognitive health platform integrating Firefly...
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”...
Firefly Neuroscience files to sell 22.5M shares of common stock for holders
08:04 EDT Firefly Neuroscience (AIFF) files to sell 22.5M shares of common stock for holders
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository
- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -
Firefly enters Department of War partnership for PTSD, TBI treatment
Firefly Neuroscience (AIFF) announced a partnership with the Department of War to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic St...
Firefly Confirms Public-Private Partnership with the Department of War
Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members
Firefly says EEG/ERP technology may help identify ADHD subtypes
Firefly Neuroscience (AIFF) announced the advancement of research using Resting EEG/Cognitive EEG brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the th...
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1
Firefly Neuroscience announces 20-fold expansion of commercial footprint
Firefly Neuroscience (AIFF) announces a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of Evoke Neuroscience an...
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-dr...
Firefly Neuroscience files $250M mixed securities shelf
17:01 EST Firefly Neuroscience (AIFF) files $250M mixed securities shelf
Firefly Neuroscience reports Q3 EPS (20c) vs. (61c) last year
Reports Q3 revenue $388,000 vs. $33,000 last year. “As demonstrated by our revenue growth, reduced cost structure and improved bottom line in Q3-2025, we have been able to rapidly integrate…
Firefly Neuroscience Reports Third Quarter 2025 Financial Results
– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan ...
Firefly Neuroscience partners with HealingMaps for electrophysiology analytics
Firefly Neuroscience (AIFF) announced a new partnership with HealingMaps and Advanced Behavioral Strategies. The collaboration comes on the heels of HealingMaps and Capstone Management Group announcin...
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improv...
Firefly Neuroscience unveils new CLEAR Platform
Firefly Neuroscience (AIFF) unveiled its new ‘CLEAR’ Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled electroencephalogram data quality. The CLEAR Platfo...
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR' Platform
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months aft...
Firefly Neuroscience files to sell 6M shares of common stock for holders
06:04 EDT Firefly Neuroscience (AIFF) files to sell 6M shares of common stock for holders
Firefly Neuroscience enter commercial agreement for use of BNA platform
Firefly Neuroscience (AIFF) highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Huma...
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architecture in...